We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+13.73%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$178M
AUM Growth
+$74.8M
Cap. Flow
+$62M
Cap. Flow %
34.75%
Top 10 Hldgs %
63.3%
Holding
53
New
10
Increased
20
Reduced
12
Closed
3

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.4M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$4.04M
3
IBB icon
iShares Biotechnology ETF
IBB
+$2.09M
4
PCRX icon
Pacira BioSciences
PCRX
+$1.96M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$936K

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$24.3M
2
MDVN
MEDIVATION, INC.
MDVN
+$3.11M
3
IQV icon
IQVIA
IQV
+$1.42M
4
HOLX
Hologic
HOLX
+$571K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$291K

Sector Composition

Rank Sector Weight
1 Healthcare 42.47%
2 Real Estate 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOLX
51
DELISTED
Hologic
HOLX
– –
-16,500
Closed -$571K
IWM icon
52
iShares Russell 2000 ETF
IWM
$79.1B
– –
-200,000
Closed -$24.3M
MDVN
53
DELISTED
MEDIVATION, INC.
MDVN
– –
-51,561
Closed -$3.11M
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q3 2016 Portfolio in Review

As of Q3 2016, Opus Point Partners Management held 53 positions worth $178M, up 72% from $104M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management deployed $62M of net new capital in Q3 2016, opening 10 new positions and adding to 20 existing holdings. Its largest new stake was ProShares Ultra NASDAQ Biotechnology: 85,000 shares worth $4.12M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 62% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was IQVIA, an estimated $1.42M trimmed.

  • Opus Point Partners Management's largest Q3 2016 buy was ProShares Ultra NASDAQ Biotechnology: 85,000 shares worth $4.12M.
  • Opus Point Partners Management added most to State Street SPDR S&P Biotech ETF in Q3 2016, an estimated $4.4M increase.
  • Opus Point Partners Management's biggest Q3 2016 reduction was IQVIA, cutting an estimated $1.42M.
  • Opus Point Partners Management fully exited iShares Russell 2000 ETF in Q3 2016, selling an estimated $24.3M.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $178M portfolio in Q3 2016.
  • Opus Point Partners Management opened 10 new positions and closed 3 in Q3 2016.
  • Opus Point Partners Management's portfolio value rose 72% quarter-over-quarter to $178M.

Based on Opus Point Partners Management's 13F filing for Q3 2016, filed 14 Nov 2016.